Advanced in Otitis Media with Effusion

Nobuhiko Oridate

Yokohama, JP 
Advanced in Otitis Media with Effusion
Yokohama, JP 
OverviewLocationsClinical Research

Overview

Nobuhiko Oridate practices in Yokohama, Japan. Oridate is rated as an Advanced expert by MediFind in the treatment of Otitis Media with Effusion. Their top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Throat Cancer, Laryngeal Cancer, Laryngectomy, and Myringotomy.

Their clinical research consists of co-authoring 139 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 4 articles in the study of Otitis Media with Effusion.

Locations

Yokohama, Japan
Other Locations
Head And Neck Surgery, Sendagi, Japan
Department Of Otolaryngology Head And Neck Surgery, Kita 15, Nishi 7, Kita Ku, Sapporo, 0608638, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
Enrollment Status: Terminated
Publish Date: June 13, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 3
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
View 1 Less Clinical Trial

139 Total Publications

Usefulness of bilateral traction method for endoscopic submucosal dissection of superficial pharyngeal cancer.
Usefulness of bilateral traction method for endoscopic submucosal dissection of superficial pharyngeal cancer.
Journal: Endoscopy
Published: July 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Oridate's expertise for a condition
ConditionClose
View All 21 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile